IORT Facts

TARGIT trials

TARGIT IORT has been extensively tested in clinical trials over the past 15 years. The TARGIT-A trial, included 3451 patients treated in 33 hospitals in UK, Europe, USA and Australia and this trial compared IORT with traditional radiotherapy.

Compared with traditional radiotherapy, TARGIT IORT has only minimal side effects. When given at the time of surgery the five-year survival rates are similar (93.9% TARGIT IORT versus 92.9% traditional RT).

While women with certain tumour types (hormone positive) may be more suitable than others, patients with estrogen receptor negative tumours, or those who are HER2 positive (Herceptin receptor positive) may still be offered intraoperative radiotherapy. The use of IORT is these patients call allow a boost of radiotherapy to the breast at the site of the cancer and reduce the number and durations of traditional radiotherapy treatments.


Key Benefits

  • Takes less time: TARGIT IORT is given during your surgery rather than after a six week delay before a three or four week course of traditional radiotherapy.
  • Precise radiotherapy: The radiotherapy is given into the breast exactly where the cancer had been, ensuring that it is accurately delivered.
  • Protects health tissues: There is reduced toxicity or damage to the skin, heart or lungs.
  • Avoids delay: Radiotherapy does not need to be delayed until after chemotherapy.
  • Flexible for your needs: TARGIT IORT can be supplemented with whole breast radiotherapy if it is thought necessary later on

Key Concerns

  • Possible need for further radiotherapy: About 15-20% of patients may need to receive traditional radiotherapy in addition to TARGIT IORT if it is felt necessary after detailed examination of the tumour
  • Some uncertainty about the results: The safety of TARGIT IORT is well established but not all patients’ follow-up data beyond five years is available yet. It is possible that the risk of disease returning may be 1% higher than after traditional radiotherapy. However, there is a lower mortality (approximately 1%) with TARGIT IORT compared with standard radiotherapy treatments.